Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.

导出 OA

翻译打印收藏纠错

作者： Susan L,Samson ^[1] ; Lisa B,Nachtigall ^[2] ; Maria,Fleseriu ^[3] ; Murray B,Gordon ^[4] ; Marek,Bolanowski ^[5] ; Artak,Labadzhyan ^[6] ; Ehud,Ur ^[7] ; Mark,Molitch ^[8] ; William H,Ludlam ^[9] ; Gary,Patou ^[9] ; Asi,Haviv ^[9] ; Nienke,Biermasz ^[10] ; Andrea,Giustina ^[11] ; Peter J,Trainer ^[12] ; Christian J,Strasburger ^[13] ; Laurence,Kennedy ^[14] ; Shlomo,Melmed ^[6]

作者单位： Pituitary Center, Baylor St. Luke's Medical Center, Baylor College of Medicine, Houston, Texas, USA. ^[1] Neuroendocrine Unit, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. ^[2] Pituitary Center, Oregon Health & Sciences University, Portland, Oregon, USA. ^[3] Allegheny Neuroendocrinology Center, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA. ^[4] Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wroclaw, Poland. ^[5] Cedars-Sinai Medical Center, Los Angeles, California, USA. ^[6] University of British Columbia, Vancouver BC, Canada. ^[7] Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. ^[8] Chiasma Inc, Needham, Massachusetts, USA. ^[9] Leiden University Medical Center, Oegstgeest, Netherlands. ^[10] Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University, Milan, Italy. ^[11] The Christie NHS Foundation Trust, Manchester, UK. ^[12] Clinical Endocrinology, Charite-Universitätsmedizin, Campus Mitte, Berlin, Germany. ^[13] Cleveland Clinic Foundation, Cleveland, Ohio, USA. ^[14]

关键词 oral octreotide IGF-1 acromegaly growth hormone somatostatin analogues somatostatin receptor ligands